CCF FB LIVE Emily Bergsland MD March 25

Emily Bergsland, MD

Gastrointestinal Oncologist

University of California San Francisco (UCSF)

Helen Diller Family Comprehensive Cancer Center


Emily Bergsland, MD,  gastrointestinal oncologist at the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, California, is the featured guest for Luncheon with the Experts on Thursday, March 25, 2021. Dr. Bergsland is Professor of Clinical Medicine, UCSF; Associate Director for Education, Helen Diller Family Comprehensive Cancer Center; and holds the Ernest Rosenbaum, MD, Endowed Chair in Medical Oncology, UCSF. Her expertise includes treating colorectal and other gastrointestinal cancers, with an emphasis on neuroendocrine tumors (NETs) and colorectal malignancies.

In her research, Dr. Bergsland focuses on developing and testing new cancer therapies, with an emphasis on NETs. She has also written extensively on the evolution of neuroendocrine tumor treatment. Dr. Bergsland has led numerous clinical studies in patients with gastrointestinal malignancies. Her current efforts are focused on clinical and translational research related to neuroendocrine tumors.

At a national level, Dr. Bergsland is a member of the NCCN (National Comprehensive Cancer Network) NET guidelines panel and past Chair of the Neuroendocrine Tumor Task Force for the National Cancer Institute. She is also the study chair for a national study of a novel treatment for patients with carcinoid tumors performed by the ALLIANCE for Clinical Trials and funded by the National Cancer Institute. Dr. Bergsland currently serves as President of the North American Neuroendocrine Tumor Society (NANETS).


• To make an appointment with Dr. Bergsland, click here:

• UCSF Center for Neuroendocrine Tumors,


NEW UCSF E-Study for NET Patients: 


Selected Publications:

• North American Neuroendocrine Tumor Society Guide for Neuroendocrine Tumor Patient Health Care Providers During COVID-19,

• Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic: Are There Any Concerns?

• New frontiers in imaging including radiomics updates for pancreatic neuroendocrine neoplasms (abstract),

• Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasms,

• Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of the 2015 European Neuroendocrine Tumor Society Expert Consensus Guidelines,

• The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors,

• The Surgical Management of Small Bowel Neuroendocrine Tumors, Consensus Guidelines of the North American Neuroendocrine Tumor Society,

• NANETS’ Position Statement COVID-19 Vaccination for NEN patients,

• Additional publications,


Selected Research:


Selected Videos and Interviews:

The ABC’s of Neuroendocrine Cancer: 2020 Update,

Peptide Receptor Radionuclide Therapy (PRRT),

Neuroendocrine Tumor Guidelines,

NET Basics: Types of NETs, Common Treatments, and What You Should Know about Your Tumor,

Expert Shares Treatment Updates for Neuroendocrine Tumors,

UCSF’s Dr. Emily Bergsland on Understanding Clinical Trials,


Social Media:

UCSF Hellen Diller Family Comprehensive Cancer Center on Twitter, @UCSFCancer,

UCSF Hospitals on Twitter, @UCSFHospitals,

UC San Francisco on Twitter, @UCSF,

UCSF Helen Diller Family Comprehensive Cancer Center on Facebook, @DillerCancerCenter,

NANETS, the North American Neuroendocrine Tumor Society, on Twitter, @NANETS1,

NANETS on Facebook, @NANETS,

Print Friendly, PDF & Email